APC-366 tryptase inhibitor data

ARRS announced results from a Phase IIa trial of its tryptase inhibitor in allergen-induced bronchial hyperresponsiveness. APC-366 protected against allergen-induced early and late airway responses, and against histamine-induced bronchial hyperresponsiveness. Early allergen response was reduced by a statistically significant amount (p<0.04) in the combined treatment groups (2.5 and 5 mg). The 2.5 mg dose provided 42 percent protection against late airway response (p<0.05) compared to baseline response before treatment. A higher degree of protection against late airway response was seen at the 5 mg dose, but the 62 percent protection was not statistically significant. ...